Treatments

Through extraordinary innovation, OvaScience seeks to transform the world’s understanding of a woman’s biology and empower women worldwide.

OvaScience is developing and commercializing egg-focused treatment options for women who are facing challenges with their fertility.

Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The OvaScience treatments have the potential to increase IVF success rates by improving egg health, increasing egg reserve and developing the next generation of IVF.

To learn more about OvaScience’s treatment options, contact us.

AUGMENTSM Treatment

The AUGMENT treatment (launched in certain IVF clinics in select international regions in 2014) is specifically designed to improve a patient’s egg health. Improved egg health may offer the potential for enhanced IVF.

Visit Augment Treatment Site

Request information about the Augment Treatment

OvaPrimeSM Treatment

The OvaPrime treatment is a potential fertility option that could enable a woman to increase her egg reserve.

OvaTureSM Treatment

The OvaTure treatment (currently in preclinical development) is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections.

Making a Difference

Through extraordinary innovation, OvaScience seeks to transform the world’s understanding of a woman’s biology and empower women worldwide. The Company’s treatments focus on addressing the following:

INCREASING LIVE BIRTH RATES AND REDUCING THE NUMBER OF IVF CYCLES

By improving egg health, we believe we may increase the number of higher quality embryos resulting from an IVF cycle and, in so doing, reduce the IVF cycles required.

REDUCING THE INCIDENCE OF MULTIPLE BIRTHS

OvaScience’s EggPC technology may allow for the transfer of fewer embryos per cycle and, as a result, lower the incidence of multiple births and the associated complications.

LOWERING THE OVERALL COST OF IVF

If we reduce the number of IVF cycles required for a live birth and reduce the incidence of multiple births, we believe our treatments also may lower the overall costs associated with IVF.

REDUCING THE NEED FOR HORMONAL HYPERSTIMULATION

Currently in preclinical development, the OvaTureSM treatment could reduce, or possibly eliminate, the need for hormonal hyperstimulation for the maturation of fertilizable eggs.

This website contains information about the AUGMENTSM treatment, which is available in certain IVF clinics in select international countries. The AUGMENT treatment is not available in the United States. Each country has specific laws, regulations and medical practices governing the communication of information about medical treatments. This is not a solicitation or promotion for any treatment which is not authorized by the laws and regulations of the country where the reader resides.